The 36-month beta value for BLUE is also noteworthy at 0.71. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for BLUE is 9.61M, and at present, short sellers hold a 26.31% of that float. The average trading volume of BLUE on February 21, 2025 was 388.83K shares.
BLUE) stock’s latest price update
The stock price of Bluebird bio Inc (NASDAQ: BLUE) has dropped by -40.48 compared to previous close of 7.04. Despite this, the company has seen a fall of -42.21% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-21 that PHILADELPHIA, PA / ACCESS Newswire / February 21, 2025 / Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by “funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP (“SK Capital”) in collaboration with a team of highly experienced biotech executives.
BLUE’s Market Performance
BLUE’s stock has fallen by -42.21% in the past week, with a monthly drop of -46.56% and a quarterly drop of -37.09%. The volatility ratio for the week is 10.17% while the volatility levels for the last 30 days are 8.44% for Bluebird bio Inc The simple moving average for the last 20 days is -39.77% for BLUE’s stock, with a simple moving average of -68.03% for the last 200 days.
Analysts’ Opinion of BLUE
BofA Securities, on the other hand, stated in their research note that they expect to see BLUE reach a price target of $0.50, previously predicting the price at $3. The rating they have provided for BLUE stocks is “Neutral” according to the report published on November 15th, 2024.
BLUE Trading at -46.19% from the 50-Day Moving Average
After a stumble in the market that brought BLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.09% of loss for the given period.
Volatility was left at 8.44%, however, over the last 30 days, the volatility rate increased by 10.17%, as shares sank -45.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.77% lower at present.
During the last 5 trading sessions, BLUE fell by -40.69%, which changed the moving average for the period of 200-days by -76.11% in comparison to the 20-day moving average, which settled at $6.96. In addition, Bluebird bio Inc saw -49.76% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BLUE starting from Klima Thomas J, who sale 122 shares at the price of $7.39 back on Feb 03 ’25. After this action, Klima Thomas J now owns 8,378 shares of Bluebird bio Inc, valued at $902 using the latest closing price.
Colvin Richard A, the Chief Medical Officer of Bluebird bio Inc, sale 64 shares at $7.39 during a trade that took place back on Feb 03 ’25, which means that Colvin Richard A is holding 8,194 shares at $473 based on the most recent closing price.
Stock Fundamentals for BLUE
Current profitability levels for the company are sitting at:
- -5.96 for the present operating margin
- -0.43 for the gross margin
The net margin for Bluebird bio Inc stands at -5.66. The total capital return value is set at -1.87. Equity return is now at value -270.20, with -54.29 for asset returns.
Based on Bluebird bio Inc (BLUE), the company’s capital structure generated 1.02 points at debt to capital in total, while cash flow to debt ratio is standing at -0.61. The debt to equity ratio resting at -63.67. The interest coverage ratio of the stock is -19.69.
Currently, EBITDA for the company is -167.16 million with net debt to EBITDA at -2.32. When we switch over and look at the enterprise to sales, we see a ratio of 6.41. The receivables turnover for the company is 3.71for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.51.
Conclusion
In summary, Bluebird bio Inc (BLUE) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
